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ABSTRACT
Background. Penile cancer is a rare disease and surgical
treatment often entails a significant impact on quality of
life. The aim of this study was to analyze trends in surgical
treatment patterns in Germany.
Methods. We analyzed data from the nationwide German
hospital billing database and the German cancer registry
from 2006 to 2016. All penile cancer cases with penile
surgery or lymph node dissection (LND) were included.
We also analyzed the distribution of cases, extent of sur-
gery, and length of hospital stay, stratified for annual
caseload. The geographical distribution of centers for 2016
was presented.
Results. During the investigated timespan, tumor inci-
dences increased from 748 to 971 (p = 0.001). We
identified 11,353 penile surgery cases, increasing from 886
to 1196 (p\ 0.001), and 5173 cases of LND, increasing
from 332 to 590 (p\ 0.001). Cases of partial amputation
increased from 45.8 to 53.8% (p \ 0.001), while total
amputation remained stable at 11.2%. Caseload in high-
volume hospitals increased from 9.0 to 18.8% for penile
surgery (p\ 0.001) and from 0 to 13.1% for LND (p\
0.001). The increase in LND caseload was caused by an
increase in inguinal LND, from 297 to 505 (p \ 0.001),
with increasing sentinel LND, from 14.2 to 21.9% (p =
0.098). The assessment of geographical distribution of
cases in Germany revealed extensive areas without suffi-
cient coverage by experienced centers.
Conclusions. We saw consistent increases in penile sur-
gery and LND, with a growing number of cases in high-
volume hospitals, and, accordingly, an increase in tumor
incidence. The increasing use of inguinal LND and organ-
preserving surgery reflect the adaptation of current guide-
lines; however, geographical distribution of experienced
centers could be improved.
Penile cancer is a rare disease in Western countries, with
a varying incidence from 0.4 to 1.8 per 100,000 cases (age-
standardized rate [ASR]) and predominantly affecting men
[60 years of age.1–3 About one-third of cases are attrib-
uted to past human papillomavirus (HPV) infections of the
penile skin, whereas the remaining cases seem to be mostly
generated by chronic inflammatory processes of the glans
and prepuce.4 Since, after childhood circumcision, men
show far lower incidences of penile cancer, removing the
prepuce seems to have a preventive effect.1
When removed locally before metastasis or local pro-
gression, penile cancer can be safely cured, with only a
little impact on the patients’ quality of life and sexual
function. However, after local progression with vascular,
corporal, or urethral invasion, mutilating surgery with
partial or total amputation of the penis is the only reason-
able option.4,5 In a locally advanced stage with [ pT1b
tumors or suspicion of lymph node metastasis, additional
inguinal lymph node dissection (LND) should be per-
formed according to the European Association of Urology
guidelines for penile cancer,6 followed by pelvic LND if
inguinal lymph nodes prove positive or in cases of radio-
graphically suspicious pelvic lymph nodes. In cases of
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lymph node recurrence or extensive nodal metastasis,
5-year survival rates drop to B40%, depending on
chemotherapy response.7 Despite currently ongoing studies
with immune checkpoint inhibitors,8 data on possible
effects are limited and, to date, prognosis for men with
metastatic disease remains poor.4
Due to the low incidence of the disease, with about 900
newly diagnosed cases in Germany in 2014,9 experience
with surgical and systemic treatment of penile cancer in
about 330 urological clinics is expected to be rather low on
average. However, numerous studies have proven a cor-
relation between surgical management of malignant
diseases and improved survival, as well as functional out-
comes.10–14 For men with penile cancer requiring at least
partial amputation of the penis, surgical experience is all
the more important since skilled organ-preserving or
reconstructive surgery can help to maintain quality of life
and sexual function.7 Consequently, guidelines strongly
recommend referring those patients to specialized cen-
ters.6,15 However, data on recent treatment patterns for the
surgical management of penile cancer in Germany are
lacking.
The aim of this study was to assess current trends of
penile cancer surgery and LND in Germany. These
developments should be analyzed with regard to the overall
disease incidence and the regional distribution of care
providers in order to derive possible optimizations.
METHODS
Data Sources
The nationwide hospital billing database of the German
Federal Statistical Office was used as the primary data
source. The data extraction and cohort identification
methods have been described in previous publications.16
The diagnosis is coded according to the standard Interna-
tional Classification of Diseases, Tenth Revision (ICD-10)
coding system, while Operationen und Prozeduren-
schluessel (OPS), a German version of the International
Classification of Procedures in Medicine, is implemented
for procedures. The database is composed by the annual
hospital billing data sets being transferred, according to
legal obligation by German hospitals, to the Federal Sta-
tistical Office. The data are virtually complete for the given
purpose.
Inclusion criteria were a diagnosis of penile cancer
(ICD-10: C.60), uncertain neoplasm of the penile skin
(D.407) or Bowen’s disease (D.074) combined with either
penile surgery (OPS: 5-641, 5-642) or inguinal LND (5-
401.5, 5-401.a, 5-402.4, 5-402.9, 5-404.h) or pelvic LND
(OPS: 5-401.4, 5-401.9, 5-402.3, 5-402.5, 5-402.8, 5-404.f,
5-404.g). The surgical approach of penile surgery was
grouped as excision or destruction of the primary tumor
(OPS: 5-641), or partial (OPS: 5-642.0) or total amputation
(OPS: 5-642.1, 5-642.2). Pelvic LND could be divided into
an open (OPS: 5-401.4, 5-402.3, 5-402.5, 5-404.f) or
laparoscopic approach (OPS: 5-401.9, 5-402.8, 5-404.g).
The extent of inguinal LND was defined through ICD
coding as sentinel (OPS: 5-401.5, 5-401.a), modified/re-
duced bilateral (OPS: 5-402.4, 5-402.9), or radical (OPS:
5-404.h). Additional assessment of surgical revision or
complication management was performed using OPS codes
8-159.2, 8-148, and 8-149 (drainage of a lymphocele), OPS
code 5-408 (lymphocele resection), or OPS codes 5-894,
5-895, 5-896, and 5-869.1 (treatment for wound-healing
disorders).
The existing database was supplemented with additional
institutional characteristics (i.e. teaching status, hospital
size, and location). Annual hospital caseload categories
were defined as low (\ 4), medium (4–9), and high (C 10)
according to our previous work in less frequent entities.17
We supplemented estimates on the nationwide incidence
of penile cancer from the German National Centre for
Cancer Registry Data at the Robert Koch Institute,18 which
are presented in absolute numbers and as age-standardized
incidence rates (old European standard population). We
further used data from 14 (of 16) German cancer registries,
representing 79% of the German male population whose
data were available for the whole study period, to calculate
tumor stage distribution and cases of histological types of
penile cancer.
For identification of national providers and geographical
localization, data from QB-Monitor 2016 and EasyMap
(Lutum ? Tappert DV-Beratung GmbH, Bonn, Germany)
were implemented. Herein, we conducted a systematic
search for cases with OPS codes of inguinal LND and
penile (partial) amputation (see above). Non-urological
cases were excluded from the analysis.
Statistics
Rates, means, and trends were compared using the
correlation coefficient and Wald tests. Rates and percent-
ages of absolute values were predominantly used, and rates
of relative values are distinctly specified. For trend analysis
over time, F-tests of the linear regression coefficient of the
annual caseload development were used. A p-value\ 0.05
was regarded as significant. For statistical analysis SAS 9.4
(SAS Institute GmbH, Heidelberg, Germany) was used.
The included data were derived from fully anonymized
databases with a high level of data protection. We followed
the REporting of studies Conducted using Observational
Routinely collected health Data statement (RECORD).19
Centralization for High-Quality Penile Cancer Surgery in Germany 9191
RESULTS
Epidemiology
According to the cancer registry data, the absolute
incidence of penile cancer in Germany increased steadily
from 748 cases in 2006 to 971 cases in 2016 (p\0.001 for
trend analysis); however, the ASR remained fairly
stable between 1.4 and 1.6/100,000 cases during the
investigated timespan (p = 0.15). The mean age of penile
cancer patients increased from 67.2 ± 11.9 years in 2006 to
69.3 ± 12.1 years in 2016 (p = 0.001). Overall, 14.4% of
patients presented with lymph node metastasis and 2.9% of
patients presented with distant metastasis at primary diag-
nosis. Primary histology was squamous cell carcinoma in
92.6% of cases, melanoma in 1.1%, adenocarcinoma in
0.9%, basal cell carcinoma in 0.8%, and not specified
penile malignancies in 4.6% of cases. Figure 1 shows the
development of the incidence of tumor stages and meta-
static disease.
Penile Cancer Surgery
A total of 11,353 cases of penile surgery for penile
carcinoma were extracted from the DRG database, with
increasing annual numbers from 886 in 2006 to 1196 in
2016 [p \ 0.001]. The average number of hospitals was
330.2 per year, increasing from 311 in 2006 to 350 in 2016.
Patient characteristics and patterns of care for penile sur-
gery and LND are presented in Table 1. Mean patient age
increased from 66.1 ± 13.0 years in 2006 to 68.5 ± 12.5
years in 2016 (p\0.001). Figure 2 demonstrates the trends
in caseload and surgical extent. Cases of partial amputation
increased from 45.8% to 53.8% (p \ 0.001), while total
amputation remained stable at 11.2% and local excision/
destruction declined from 43.9 to 35.7% (p = 0.035). A
laser was used in 7.1% of cases. Primary lesions were
situated at the prepuce in 7.2% of cases, glans in 44.8%,
and shaft in 5.6% of cases, with overlapping or uncertain
location in 6.1% and 7.0% of cases, respectively.
Figure 3a shows the volume of penile cancer surgery
according to the hospital caseload category. The share of
patients treated in hospitals with high volume increased
from 9.0% in 2006 to 18.8% in 2016, but decreased in
hospitals with an annual caseload of \ 4, from 44.5 to
35.3% (p = 0.001 for trend comparison).
Lymph Node Dissection
Overall, 5173 cases of LND for penile carcinoma were
included for analysis, increasing considerably from 332 in
2006 to 590 in 2016 (p\ 0.001). The mean age at LND
increased from 63.0 ± 11.6 years to 65.4 ± 11.3 years (p\
0.001). The increase in caseload was mainly caused by an
increase in inguinal LNDs, from 297 to 505 (p\ 0.001).
The share of pelvic LNDs remained stable at 16.1% of
cases (average of 17.5% laparoscopically). There was a
non-significant increase, from 14.2% in 2006 to 21.9% in
2016 (p = 0.098), for applying the sentinel technique with
inguinal LND. Figure 3b presents the caseload distribution
for LND according to the hospital caseload category. The
share of patients treated in high-volume hospitals increased
from 0% in 2006 to 13.1% in 2016 (p \ 0.001), but

































































































FIG. 1 Development of tumor stages (a) and lymph node stages and
other metastasis (b) at first diagnosis for penile cancer in Germany
(2006–2016; 60% of the total population). N?, M? lymph node and
other metastasis, M? other metastasis, lymph node-negative, N?
lymph node metastasis only, N0, M0 no metastasis, Nx, Mx metastasis
unclear
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(p = 0.008). A mean of 95.8% of cases were performed in
urological departments. Overall, 64.9% of hospitals per-
forming penile cancer surgery did not perform inguinal
LND for penile cancer, increasing from 49.8 to 72.3% (p\
0.001). The rate of surgical revision was 11.1%, increasing
from 6.3 to 12.5% (p \ 0.001), independent of hospital
caseload. Predominant were wound-healing disorders at
49.6%, followed by percutaneous lymphocele drainage
(34.6%) and lymphocele resection (15.8%). The overall
length of stay (LOS) for LND was 14.2 ± 11.5 days,
decreasing from 15.4 ± 10.5 in 2006 to 13.2 ± 12.6 days in
2016 (p = 0.005). LOS was shorter in high-volume hospi-
tals versus low-volume hospitals (13.0 ± 11.8 days vs. 15.0
± 12.2 days) [p = 0.002]. Patients with sentinel LND had a
shorter LOS (12.4 ± 12.5 days) than patients with modified
LND (14.2 ± 11.21 days) and radical LND (15.6 ± 12.9
days) [p\ 0.001].
Figure 4 demonstrates the distribution of cases of
inguinal LND and penile amputation (partial or radical) in
Germany, on a geographic map, for the year 2016.
DISCUSSION
From 2006 to 2016, the annual incidence of penile
cancer increased steadily (29.8%), in accordance with the
caseload for penile cancer surgery (35.0%) and LND
(53.3%). Likewise, the share of cases being performed in
hospitals with high caseloads increased for both penile
surgery and LND. The increase in LND caseload was
mainly caused by increasing inguinal LND numbers.
Inguinal LND was predominantly performed in a radical or
modified fashion, with a slight trend towards an increasing
use of the sentinel technique.
Trends of Newly Diagnosed Penile Cancer in Germany
In absolute numbers, the incidence of penile cancer in
Germany has increased steadily, by nearly one-third, dur-
ing the investigated timespan; however, the age-adjusted
incidence rate remained stable. Therefore, the increasing
incidence is mainly explained by the demographic shift,
with an increasing share of older male citizens in the
German population.20 At the same time, there was no
change in tumor stage distribution and the share of meta-
static disease (Fig. 2). When compared with penile cancer
epidemiology in the current literature, we see similar basic
incidence rates in other European populations;21 however,
the incidence rate varies in different countries and is higher
in some northern European countries, e.g. Sweden.4,22
Compared with contemporary results from the US, the
German incidence rate is higher, although current studies
demonstrated significant differences in the US itself
depending on patient ethnicity, differences in religious
practice (i.e. childhood circumcision), and socioeconomic
status.23 Histologic distribution in the US is also compa-
rable with Germany, with approximately 93% of squamous
cell carcinomas, and small percentages of melanoma,
adenocarcinoma, and basal cell carcinoma.4,23
TABLE 1 Patient
characteristics and patterns of
care of penile cancer surgery
and LND in Germany
(2006–2016)
Penile surgery LND
Total number of cases 11,353 5173
Age, years [mean ± SD] 67.3 ± 12.5 64.5 ± 11.4
Annual hospital caseload
\ 4 4446 (39.2) 2818 (54.5)
4–9 5428 (47.8) 1991 (38.5)
[ 9 1479 (13.0) 364 (7.0)
Teaching status
Academic 3110 (27.4) 3525 (68.1)
Size of hospital, no. of beds
\ 300 2194 (19.3) 870 (16.8)
301–800 4820 (42.5) 2037 (39.4)
[ 800 4339 (38.2) 2266 (43.8)
Surrounding city size, no. of inhabitants
\ 20,000 1708 (15.0) 714 (13.8)
20,001–100,000 3835 (33.8) 1721 (33.3)
100,001–500,000 3373 (29.7) 1632 (31.5)
[ 500,000 2437 (21.5) 1106 (21.4)
Data are expressed as n (%) unless otherwise specified
LND lymph node dissection, SD standard deviation
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Trends of Penile Surgery and Lymph Node Dissection
for Penile Cancer in Germany
The total number of penile surgeries for penile cancer
increased by approximately one-third during the 11-year
timespan of this study, which can be primarily explained
by the increasing incidence of penile cancer. Nevertheless,
our analysis also demonstrated that partial amputation is
used in an increasing percentage of cases, following the
guideline-recommended principle of organ
preservation.6,15 Nonetheless, this might lead to repeat
surgery instead of one-time radical treatment.4 Addition-
ally, the number of hospitals performing surgery for penile
carcinoma increased by 12.5%. Moreover, the overall
annual caseload per hospital increased, leading to a higher
number of cases being performed in hospitals with a high
caseload (Fig. 3) and thus to presumably improved exper-
tise in the respective centers. This trend is even surpassed
by the increases in total caseload of LND for penile cancer
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FIG. 2 Extent and absolute number of penile surgeries (a) and LNDs for penile cancer (b) in Germany (2006–2016). LND lymph node
dissection
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an increase in inguinal LNDs, of which we noticed a
nonsignificant increase in the percentage of sentinel ingu-
inal LNDs (from 14 to 22%), as recommended by the
European Association of Urology guidelines.6
A positive correlation between high caseload volume
and better postoperative outcomes has been repeatedly
shown in several major procedures such as radical prosta-
tectomy and radical cystectomy.10,12–14,24 Technically
challenging surgical procedures such as penile recon-
struction after partial amputation, as well as inguinal LND,
also require high levels of experience;4 however, important
endpoints such as cosmetics, functional outcomes, and
quality of life were not available in the presented datasets.
LOS was about 2 days shorter in high-volume hospitals,
although this endpoint was not a sufficient surrogate for
relevant outcomes. Due to the low overall incidence rates
and the increasing number of hospitals performing penile
surgery, the majority of cases are still performed in hos-
pitals in which fewer than 10 procedures are performed
annually; in 2016, this resulted in a rate of 81% for penile
surgery and 87% for LND. National health policy making

















































FIG. 3 Distribution of patients with penile surgery (a) and LND (b) in Germany, stratified for annual hospital caseload categories (2006–2016).
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FIG. 4 Distribution of (partial) penile amputation (a) and inguinal LND (b) in urologic departments for the year 2016. LND lymph node
dissection
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penile cancer in general and for surgical treatment in par-
ticular. One option could be the implementation of
minimum caseload requirements, as already applied in
Germany since 2004, for selected surgical procedures and
treatments, with limited effect to date.25 Another option
could be the certification of specialized penile cancer
centers, with several European countries having established
specialized centers for penile cancer, e.g. the Scandinavian
countries.4,26 or the UK21,27 The advantages of centralized
treatment were shown for the timely referral from diag-
nosis to treatment,26 accuracy of the pathological
assessment,21 and survival rates.27 Furthermore, improved
guideline adherence associated with more frequent lymph
node staging was shown in European countries as well as in
the US.22,27,28 Therefore, an accelerated diagnostic process,
and treatment according to guidelines, could be selling
points for the centralization of care for penile cancer.
Geographical Distribution and Centralization
Tendencies
Since penile cancer has a high incidence in older men
with potentially reduced mobility, being able to reach a
medical center with adequate experience with reasonable
effort is of high importance. Therefore, we demonstrated
the geographical distribution of centers, along with their
surgical caseload, for the year 2016 (Fig. 4). The results
showed a vast distribution of penile (partial) amputation as
well as inguinal LND throughout Germany, with concen-
tration to several centers in the north and west (5 for LND,
15 for penile surgery). On the one hand, this demonstrates
the adequate implementation of guideline-requested inva-
sive lymph node staging,6,15 while on the other hand,
especially in the rural areas of federal states with a larger
geographical extension (e.g. Bavaria, Brandenburg, Lower
Saxony), extensive areas exist without hospitals with ade-
quate experience in penile cancer surgery. For respective
patients, the next experienced urologic center can be
located several hours away. Health policy measures with
defining regional centers could concentrate the available
caseload to institutions with an equal geographical distri-
bution, and thereby create further experienced providers of
penile cancer care.
Limitations and Strengths
Our study was the first to analyze treatment patterns of
penile surgery and LND for penile cancer in Germany using
total population data covering 11 years to depict possible
developments over time. Adding national cancer registry
data and the regional distribution of penile cancer care pro-
viders complemented these total population data to draw a
more complete picture of the German situation. Our study
focused exclusively on surgical treatment, however systemic
treatment and radiotherapy are also important cornerstones
in the treatment of penile carcinoma, but were not included in
our analysis. The main study limitations lie in the nature of
the data itself. Although billing data are highly accurate,
detailed information on tumor and patient characteristics is
not available. Due to data protection regulations, single
patients or institutions may not be identified from the Ger-
man DRG database. Therefore, revision and verification of
each data set is not possible. Due to the data structure,
additional hospital stays or outpatient treatment of the same
patient are not assignable and outcomes can only be deter-
mined for the duration of the inpatient stay. Therefore,
patient-reported outcome measures and survival outcomes
are missing. This information is essential to provide the
rationale for designating certain institutions as ‘quality
centers’. Finally, for the analyses of tumor stage distribution
and histology, data from 2 of 16 German federal states were
excluded as these registries did not cover the whole study
period. Therefore, the presented results rely on 79% of the
estimated incidence of penile cancer cases. Given the
extensive caseload numbers for this rare procedure, some
slight variances and small irregularities appear to be negli-
gible; however, the principal risk of systematic bias has to be
kept in mind when interpreting the results.
CONCLUSIONS
We saw consistent increases in caseload numbers for
penile surgery and LND, in relation to penile cancer in
Germany, of 35% and 53%, respectively, over an 11-year
period, and, accordingly, an increase in penile cancer
incidence by approximately 30%. Surgical experience
increased in the respective hospitals, along with the rising
caseload numbers. Increasing numbers of inguinal LNDs
and organ-preserving surgeries reflect the ongoing adap-
tation of current guideline recommendations. Nevertheless,
geographical distribution of experienced centers in Ger-
many could be improved by respective health policy-
making in order to provide patients with adequate treat-
ment in their regional areas.
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6. Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C,
Watkin N. Guidelines on penile cancer. European Association of
Urology; 2020. ISBN: 978-94-92671-07-3.
7. Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S.
Recurrence patterns of squamous cell carcinoma of the penis:
recommendations for follow-up based on a two-centre analysis of
700 patients. Eur Urol. 2008;54(1):161–8. https://doi.org/10.101
6/j.eururo.2008.04.016.
8. Thana M, Wood L. Immune checkpoint inhibitors in genitouri-
nary malignancies. Curr Oncol. 2020;27(Suppl 2):S69–77. h
ttps://doi.org/10.3747/co.27.5121.
9. Robert Koch Institut. Krebsgeschehen in Deutschland 2014.
Berlin: Robert Koch Institut; 2014.
10. Barocas DA, Mitchell R, Chang SS, Cookson MS. Impact of
surgeon and hospital volume on outcomes of radical prostatec-
tomy. Urol Oncol. 2010;28(3):243–50. https://doi.org/10.1016/j.
urolonc.2009.03.001.
11. Bruins HM, Veskimae E, Hernandez V, Neuzillet Y, Cathomas R,
Comperat EM, et al. The importance of hospital and surgeon
volume as major determinants of morbidity and mortality after
radical cystectomy for bladder cancer: a systematic review and
recommendations by the European Association of Urology
Muscle-invasive and Metastatic Bladder Cancer Guideline Panel.
Eur Urol Oncol. 2020;3(2):131–44. https://doi.org/10.1016/j.euo.
2019.11.005.
12. Goossens-Laan CA, Gooiker GA, van Gijn W, Post PN, Bosch
JL, Kil PJ, et al. A systematic review and meta-analysis of the
relationship between hospital/surgeon volume and outcome for
radical cystectomy: an update for the ongoing debate. Eur Urol.
2011;59(5):775–83. https://doi.org/10.1016/j.eururo.2011.01.037.
13. Groeben C, Koch R, Baunacke M, Borkowetz A, Wirth MP,
Huber J. In-hospital outcomes after radical cystectomy for blad-
der cancer: comparing national trends in the United States and
Germany from 2006 to 2014. Urol Int. 2019;102(3):284–92. h
ttps://doi.org/10.1159/000496347.
14. Groeben C, Koch R, Baunacke M, Wirth MP, Huber J. High
volume is the key for improving in-hospital outcomes after rad-
ical prostatectomy: a total population analysis in Germany from




(Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-
Leitlinie Diagnostik, Therapie und Nachsorge des Peniskarzi-
noms, Langversion 1.0, 2020, AWMF Registernummer:
043-042OL.
16. Groeben C, Koch R, Baunacke M, Wirth MP, Huber J. Robots
drive the German radical prostatectomy market: a total popula-
tion analysis from 2006 to 2013. Prostate Cancer Prostatic Dis.
2016;19(4):412–6. https://doi.org/10.1038/pcan.2016.34.
17. Groeben C, Koch R, Nestler T, Kraywinkel K, Borkowetz A,
Wenzel S, et al. Centralization tendencies of retroperitoneal
lymph node dissection for testicular cancer in Germany? A total
population-based analysis from 2006 to 2015. World J Urol.
Centralization for High-Quality Penile Cancer Surgery in Germany 9197
2020;38(7):1765–72. https://doi.org/10.1007/s00345-019-02972-
8.
18. Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig
SR, et al. Integrated prostate cancer centers might cause an
overutilization of radiotherapy for low-risk prostate cancer: a
comparison of treatment trends in the United States and Germany
from 2004 to 2011. Radiother Oncol. 2015;115(1):90–5. https://d
oi.org/10.1016/j.radonc.2015.02.024.
19. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D,
Petersen I, et al. The REporting of studies Conducted using
Observational Routinely-collected health Data (RECORD)
statement. PLoS Med. 2015;12(10):e1001885. https://doi.org/10.
1371/journal.pmed.1001885.
20. Statistische_Aemter_des_Bundes_und_der_Länder. Bevoelk-
erungs- und Haushaltsentwicklung im Bund und in den Ländern.
Wiesbaden: Statitisches Bundesamt; 2011.
21. Tang V, Clarke L, Gall Z, Shanks JH, Nonaka D, Parr NJ, et al.
Should centralized histopathological review in penile cancer be
the global standard? BJU Int. 2014;114(3):340–3. https://doi.org/
10.1111/bju.12449.
22. Kirrander P, Sherif A, Friedrich B, Lambe M, Hakansson U.
Swedish National Penile Cancer Register: incidence, tumour
characteristics, management and survival. BJU Int.
2016;17(2):287–92. https://doi.org/10.1111/bju.12993.
23. Hernandez BY, Barnholtz-Sloan J, German RR, Giuliano A,
Goodman MT, King JB, et al. Burden of invasive squamous cell
carcinoma of the penis in the United States, 1998–2003. Cancer.
2008;113(10 Suppl):2883–91. https://doi.org/10.1002/cncr.
23743.
24. Mayer EK, Bottle A, Darzi AW, Athanasiou T, Vale JA. The
volume-mortality relation for radical cystectomy in England:
retrospective analysis of hospital episode statistics. BMJ.
2010;340:c1128. https://doi.org/10.1136/bmj.c1128.
25. Peschke D, Nimptsch U, Mansky T. Achieving minimum case-
load requirements—an analysis of hospital discharge data from
2005–2011. Dtsch Arztebl Int. 2014;111(33–34):556–63. https://d
oi.org/10.3238/arztebl.2014.0556.
26. Jakobsen JK, Krarup KP, Kirrander P, Hakansson U, Kaipia A,
Perttila I, et al. Penile cancer in Scandinavia: current practice and
future perspectives. Scand J Urol. 2016;50(1):90–2. https://doi.
org/10.3109/21681805.2014.987316.
27. Williams SB, Ray-Zack MD, Hudgins HK, Oldenburg J, Trinh
QD, Nguyen PL, et al. Impact of centralizing care for geni-
tourinary malignancies to high-volume providers: a systematic
review. Eur Urol Oncol. 2019;2(3):265–73. https://doi.org/10.1
016/j.euo.2018.10.006.
28. Matulewicz RS, Flum AS, Helenowski I, Jovanovic B, Palis B,
Bilimoria KY, et al. Centralization of penile cancer management
in the United States: a combined analysis of the American Board
of Urology and National Cancer Data Base. Urology.
2016;90:82–8. https://doi.org/10.1016/j.urology.2015.12.058.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
9198 C. Groeben et al.
